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Abstract 
 
Angiogenesis, apoptosis and senescence are all cellular processes that have an impact on tumor 
development. Angiogenesis or the new vessel formation from pre-existing ones is known to be 
required for invasive tumor growth and metastasis. Apoptosis and cellular senescence are both 
considered crucial safeguards mechanisms against neoplastic transformation. The MYC oncogene 
plays an important role in the regulation of all three of these as well as many other fundamental 
processes crucial for cell growth and tumorigenesis. 
 
In the first part of this thesis we explored endothelial cell migration by the exposure of human 
vein endothelial cells (HUVECs) and human umbilical artery endothelial cells (HUAECs) to 
stable hill-shaped gradients of vascular endothelial growth factor (VEGF) and fibroblast growth 
factor 2 (FGF2). Time-lapse analysis showed that a gradient of VEGFA165 efficiently induced 
chemotaxis of endothelial cells of different vascular origin.  Stable gradients of FGF2 were able 
to attract venular but no arterial endothelial cells. In addition to the directed migration of 
endothelial cells, we also investigated the lymphatic vessel formation in the developing mice 
kidney. Immunohistochemical analysis of kidney explants and whole mount of dissected kidney 
suggested that renal lymphatic vessel formation predominately occurs via invasive sprouting 
from surrounding lymphatic plexus.  
 
In the second part of this thesis, we first aimed to clarify the relative importance of the intrinsic 
(mitochondrial) and extrinsic (death receptor) anti apoptotic pathways in the in vivo MYC driven 
transformation of hematopoietic stem cells. Expression of MYC alone resulted in the 
development of both myeloid and T-lymphoid tumors within two months after transplantation of 
HSCs.  Expression of MYC together with BCL-XL or BCL-2 (inhibiting the intrinsic pathway) 
resulted in almost immediate development of AML like disease.  In contrast, expression of MYC 
together with FLIPL (inhibiting the extrinsic pathway) did not accelerate tumorigenesis. These 
results suggest that MYC-induced transformation of HSC accelerates and polarizes hematopoietic 
tumor development towards aggressive AML by co-expression of inhibitors of the intrinsic but 
not the extrinsic pathway of apoptosis. Secondly, we aimed to determine whether 
pharmacological inhibition of cyclin dependent kinase 2 (CDK2) interferes with MYC-driven 
tumor development in vivo trough senescence.  Mice transplanted with HSCs expressing MYC 
and BCL-XL as briefly described above were treated with a specific CDK2 inhibitor on daily 
basis via intraperitoneal injections or osmotic minipumps. Despite the very aggressive AML 
development in this model, CDK2 targeting significantly delayed the onset of disease and 
improved mice survival by restoring senescence. The senescence induction correlated with 
induction of p19
ARF
, p21
CIP1
 and activation of pRb. This suggests that pro-senescence therapy via 
CDK2 inhibition should be further evaluated as a new potential strategy to combat MYC-driven 
AML and possibly other MYC-related tumors. 
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Abbreviations 
 
Arf Alternative reading frame 
ATM Ataxiatelangiectaxia mutated  
BEC Blood endothelial cell 
bHLHLZ Basic-helix-loop-helix leucine zipper 
Bim Bcl-2 interacting mediator of cell death 
BMP4 Bone morphogenic protein 4 
Cdc Cell division cycle 
Cdk Cyclin dependent kinase 
CKI Cyclin dependent kinase inhibitor 
CML Chronic myeloid leukemia 
CSC Cancer stem cell 
DBD DNA binding domain  
E Embryonic day 
EC Endothelial cell  
EGFR Epidermal growth factor receptor 
ES Embryonic stem cell  
FGF2 Basic fibroblast growth factor 
GSK Glycogen synthase kinase 
HAT Histone acetyl transferase 
HDAC Histone deacetylase 
HSC Hematopoietic stem cell  
Ink4 Inhibitor of Cdk4 
LEC Lymphatic endothelial cell 
MAPK Mitogen activated protein kinase 
Max MYC associated protein x 
MEF Mouse embryonic fibroblast 
PDGRF Platelet derived growth factor receptor 
PI3-K Phosphatidylinositol-3 kinase 
Pol I RNA polymerase I 
Pol II RNA polymerase II 
Pol III RNA polymerase III 
REF Rat embryonic fibroblast 
RTK Receptor tyrosine kinase 
SA-B-Gal Senescence-associated B-galactosidase 
Skp2 S-phase associated kinase associated protein 2 
TERT Telomerase reverse transcriptase 
TNF-α Tumor necrosis factor- α 
TNF-R Tumor necrosis receptor  
Ub Ubiquitin 
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor  
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1   Background  
Over the past century we have gained crucial knowledge about the biological processes that 
govern life. These complex processes have become clearer for us but still there is more to 
understand.  Our need to cure diseases has led us to discover new ways to combat illness that 
killed thousands before. For instance, diseases such as diabetes lead most certainly to death 
and after several efforts made by scientists in 1922 the first patient with diabetes was cured. 
Thanks to the discovery of insulin by Frederick G. Bating and Jonh Macleod, now thousands 
of people can survive and have a normal life. However, we are still fighting against 
devastating diseases including cancer. According to the World Health Organization (WHO), 
cancer is a leading cause of death worldwide, accounting for 7.6 million deaths (around 13% 
of all deaths) in 2008 and deaths from cancer worldwide are projected to continue rising, with 
an estimated 13.1 million deaths in 2030.   
 
The discovery of the double helix structure and function of the DNA has tremendously 
impacted our deep understanding of life and it is probably the most important discovery 
among all other crucial findings that have help us to decipher life. The DNA structure and 
function discovery has led us to the dissection of crucial molecular mechanisms behind tumor 
progression and other human diseases.  It has helped us to improve the ability to diagnose 
diseases and the production of pharmaceuticals to treat them. Now we know that cancer arises 
from one single cell, and that sequential accumulation of genetic lesions and epigenetic 
changes lead to cell transformation.  These genetic lesions are influenced by different factors 
such as physical, chemical and biological carcinogens.  In addition, cancer    development is 
influenced by the genetic inherited cancer predisposition of each person.  The gained 
advances in genetics and molecular biology aided us to identify and understand that the 
imbalance of oncogene and tumor suppressor genes plays a crucial role in tumor 
development. The majority of known oncogenes are mutations of certain normal "good" 
genes named proto-oncogenes [1]. These "good" genes are normally involved in the control of 
cell growth and division. In the other hand tumor suppressor genes encode for proteins that 
control cell growth, repair DNA damages and dictate to cells when to die [2]. Tumor cells 
with disturbed oncogenes and tumor suppressors take over crucial mechanism that guaranties 
uncontrolled cell survival. The intense research efforts over the past decades have led to the 
conclusion that the complexity of cancer can be reduced to a number of underlying principals. 
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It is believe that cancer share six common traits which dictates neoplastic transformation. 
These complex traits are called the hallmarks of cancer and include sustained proliferative 
signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, and activating invasion and metastasis [3]. Lately and after new 
gained insights in cancer biology, several additional hallmarks have been added to the list of 
complex traits shared by cancer cells. The new include traits are the deregulation of 
metabolism, evasion of the immune system, genomic instability and tumor-promoting 
inflammation [4]. Moreover, it has become clearer that the tumor microenvironment also 
plays a key role in tumor development. The understanding of the underlying molecular 
mechanisms behind these special and complex traits of cancer can help us to develop new 
novel strategies against human cancer.  
     
In this doctoral thesis, angiogenesis (Part I), and oncogene related apoptosis and 
senescence are explored (Part II).  Each one of these processes is believed to take part in the 
different aspects of tumor development. For instance, angiogenesis or the new blood vessel 
formation from preexisting ones is known to be required for invasive tumor growth and 
metastasis. Avascular tumors are often restricted in growth due to the lack of a blood supply. 
In order to enhance their growth and metastatic potential, tumors make an "angiogenesis 
switch" through perturbation of the local balance of proangiogenic and antiangiogenic factors 
[5].  The second vascular organ or the lymphatic system is also highly involved in tumor 
development. It is supposed that the lymphatic system is essential to the body´s surveillance 
against cancer. In fact the lymphatic system is used as escape routes for cancer cells during 
metastasis. The MYC oncoprotein regulates several cellular processes of importance for cell 
growth and division, and it is often deregulated in cancer. MYC is also an inducer of intrinsic 
safeguard mechanism against cell transformation, including apoptosis/programmed cell death 
and cellular senescence, which needs to be overcome by genetic lesions and epigenetic 
alterations during cellular transformation.  
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Part I 
 
1.1 Vascular Development 
 
 
1.1.1 Blood and lymphatic vascular system 
The lymphatic and cardiovascular systems are two major components of the vertebrate body 
and are highly involved in different critical physiological processes. The cardiovascular 
system transports nutrients, oxygen and other molecules to different tissues. During this 
transport fluid and macromolecules are extravasated to the interstitial space and drained back 
to the venous system by the lymphatic system. Both blood and lymph vessels also play key 
roles in cancer progression. Tumor vessel formation guaranties nutrient supply and also 
provides routes for cancer cells during metastasis. The blunt ended and uni-directional 
lymphatic system also fulfills other physiological functions such as lipid absorption in the 
intestinal tract, as well as transport of immune cells to lymphoid organs [6].  Blood and lymph 
vessels differ in their anatomy. The major blood vessels, the veins and arteries, are composed 
of a single layer of blood endothelium (tunica intima) surrounded by an internal elastic 
lamina, which in turn is enclosed by smooth muscle cells (tunica media). The third layer, the 
tunica adventitia, consists of connective tissue. Capillaries and post-capillary venules are 
supported by a layer of smooth muscle actin (SMA) positive pericytes (Figure 1).  
The lymphatic vascular bed is composed of a one-way network of thin-walled 
capillaries, which are found in the skin and most vascularized organs except for the central 
nervous system, bone marrow, cartilage, cornea and epidermis.  The lymph capillaries and 
smaller lymphatic vessels are composed of single layer of lymphatic endothelial cells and are 
not covered with pericytes or smooth muscle cells. Large collecting lymphatic vessels have a 
smooth muscle cell layer, basement membrane and valves which prevent back flow of lymph 
[6] ( Figure 1B and C ). 
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Figure 1. Blood and lymphatic vessel morphology A) large blood vessel B) Large lymphatic vessel structure C) 
Renal lymph (white) and blood vessels (green), unpublished data.  
 
1.1.2 Vasculogenesis 
Vasculogenesis is the process of de novo vessel formation during embryonic development 
from endothelial precursor cells, angioblasts [7]. Vasculogenesis starts in the primitive streak 
where vascular endothelial growth factor (VEGF) receptor -2 (also denoted Flk-1) positive 
cells appear in response to basic fibroblast growth factor (bFGF) and bone morphogenic 
protein 4 (BMP4). These cells are believed to be the progenitors for both blood cells and 
endothelium (haemangioblast). The progenitors migrate into the extra-embryonic yolk sac and 
on embryonic day (E) 7-E7.5 form blood island structures, which will contain an outer layer 
of endothelial precursor cells termed angioblasts and an inner mass of hematopoietic 
precursor cells. The outer cells of the blood islands, the angioblasts, undergo further 
differentiation and form a primary vascular plexus of blood vessels [8].  Inside the embryo 
mesodermal derived angioblasts differentiate into endothelial cells and form a primitive 
vascular plexus at E8-8.5. Blood circulation in the primitive plexus is dependent of the 
connection of the vascular channels to the developing heart tube at E9.0.  
 
1.1.3 Angiogenesis 
In order to achieve circulation, the vascular plexus is remodeled gradually by different 
processes where angiogenesis, the formation of new vessel from pre-existing ones, is 
involved [9]. Differentiation, regression, migration and branching are some of the events 
leading to vascular plexus maturation. An orchestra of precisely synchronized growth factors, 
receptors and other crucial molecular players are implicated in these events (7). Angiogenesis 
is taking place during embryonic development as well as during normal physiological 
conditions such as aerobic and endurance exercise, wound healing, ovulation, inflammation. 
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In addition, angiogenesis occurs during pathological conditions such as tumor growth and 
chronic inflammation. Angiogenesis is a complex process, which is regulated by interactions 
between endothelial cells and other cell types such as fibroblasts, macrophages and smooth 
muscle cells. Cellular compounds including cytokines, growth factors and extracellular matrix 
molecules mediate intercellular interactions between these cells [10].  
In the adult angiogenesis can occur either through sprouting or intussusception [11]. In 
sprouting angiogenesis, vessel formation is achieved by a well-defined program where growth 
factors that trigger the angiogenic responses are released at the site of angiogenesis. 
Endothelial cells need to detect and respond to extracellular chemical gradients by direct or 
negative migration, a process called chemotaxis.  Directed cell migration is governed by a 
well-synchronized orchestra of secreted and ECM bounded growth factors including VEFG, 
bFGF and angiopoetins [12].  
These growth factors bind to specific receptors on endothelial cells in the blood vessels. 
Growth factor binding activates different intracellular pathways, which lead to production of 
specific proteins involved in angiogenesis [13]. Enzymes such as proteases are then released 
to the extra-cellular matrix and digest basement membrane components thus allowing selected 
blood endothelial cells (ECs) to sprout from the vessel (figure 2).  
Sprouting of the ECs is followed by the formation of a stalk of proliferating cells in the 
surrounding matrix. The formed stalk is headed by a non-dividing tip cell, which prevents 
adjacent cells from converting into tip cells (figure 2) [14].  The tip cell and cells in the stalk 
contains several actin rich membrane protrusions called filopodia, which express different 
receptors for sensing secreted and cell-bound guidance cues provided by surrounding cells 
[15].  Polymerized actin bundles form the sensing filopodia and are induced by VGFR-2 
activation [15].  
After these events the ECs form solids sprouts that connect to a neighboring vessel and 
restructure into a lumen lined by endothelial cells. Finally the newly formed vessel integrates 
in the vascular network and in order to make a more stable blood vessel supporting 
circulation, pericytes and smooth cells are recruited to the newly formed vessels. In 
intussusception or splitting angiogenesis, pre-existing larger capillaries are divided into two 
new smaller vessels by ingrowth of tissue pillars [11].  
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Figure 2. Sprouting mechanisms in angiogenesis. A) Drawing of the cell tip formation B) stalk formation C) 
Experimental evidence for the formation of tip cells (T) and stalk cells (S)[14].  
 
1.1.4 Vascular endothelial growth factors (VEGFs) and their receptors 
VEGFs stimulate blood endothelial angiogenesis as well as lymphangiogenesis. The VEGFs 
are related to platelet-derived growth factors and bind as dimers to VEGF-receptors 
(VEGFRs). Ligand binding enhances receptor dimerization or heterodimerization, which in 
turn promotes autophosphorylation of intracellular domains. Phosphorylation activates 
specific downstream signals leading to cell responses such as migration, survival and 
proliferation. VEGFRs belong to the receptor tyrosine kinase (RTK) family. RTKs are 
composed of an extracellular domain where growth factors bind, a polypeptide chain 
transversing the cell membrane, and an intracellular polypeptide chain where tyrosine kinase 
activity is found. Five VEGFs have been described; VEGF-A, -B, - C, -D and placental 
growth factor (PlGF). Beside these known factors, there are other proteins structurally related 
to VEGF; parapoxvirus VEGF-E and snake venom VEGF-F. VEGF-A, -B and PlGF are 
ligands for VEGFR-1, VEGF-A and -E are ligands for VEGFR-2, and VEGF-C and D are 
ligands for VEGFR-3 (figure 3). Further, proteolytic processing of VEGF-C and D allows 
them to bind VEGFR-2 albeit with a lower affinity than to VEGFR-3 [16].  In addition, 
VEGF-C stimulation of lymphatic endothelial cells also induced the formation and activation 
of VEGFR-3/VEGFR-2 heterodimers [17].  
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Figure 3. VEGFRs / VEGFs and their interactions [17].  
 
VEGFA is a mitogen and a survival factor that specifically acts on endothelial cells and its 
expression is upregulated by hypoxia. VEGFA deficient embryos show abnormal blood 
vessels and die at midgestation [18],[19].  Disruption of the gene encoding for VEGF-C leads 
to severe edema at E12.0 and the embryos die at E15.5. The lymphatic vasculature in these 
embryos failed to develop although PROX-1 positive cells were observed in the cardinal 
veins. However, the PROX-1 positive cells failed to sprout and form lymphatic sacs 
indicating that VEGFC paracrine function is essential for the migration and survival of the 
PROX-1 committed vein endothelial cells [20]. In conclusion, of these growth factors, 
VEGFA and VEGF-C seem to be essential for embryonic survival, angiogenesis and 
lymphatic vessel formation or lymphangiogenesis.  
The VEGF-A receptors, VEGFR2 and 1 are suggested to be highly involved in 
embryonic vascular development. Transgenic mouse embryos carrying a disrupted VEGFR-2 
gene die in uterus between 8.5 and 9.5 days post-coitum, as a result of an early defect in the 
development of haematopoietic and endothelial cells[21]. VEGFR-1 signaling seems to be 
essential for endothelial cell- cell or cell matrix interactions required for vascular organization 
but not necessary for endothelial cell differentiation[22].  
VEGFR-3 is an important player in lymphangiogenesis and a key regulator in 
embryonic vessel development; it is expressed in embryonic blood vessels while it becomes 
restricted to the lymphatic vasculature in the adult[23]. Targeted inactivation of VEGFR-3 
leads to defective blood vessel development in early embryos causing fluid accumulation in 
the pericardial cavity and cardiovascular failure at E 9.5[24]. Nevertheless recently studies 
have also implicated VEGFR-3 in angiogenic sprouts. These studies suggested that VEGFR-3 
is highly expressed in areas of active angiogenesis in the intersomites and also in tip cells of 
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angiogenic sprouts in mouse retina and melanomas models[25]. The understanding of 
VEGFR dynamics in pathologies such as cancer is of great importance for the development of 
new treatments. Targeting tumor angiogenesis and lymphangiogenesis with new strategies 
will hopefully impair tumor growth and reduce the formation of metastasis.  
 
1.1.5 The origin of the lymphatic endothelial cell  
The  ‘second circulation system’ of the body, the lymphatic vascular system was first 
described around 400 BC by Hippocrates, who saw vessels containing “white blood”. In 1627 
Gasparo Aselli, an Italian anatomist, described the lymphatic system in well fed dog guts as 
milky ways (Figure 5A). Later on in the beginning of the last century the anatomist Florence 
R. Sabin (1902-1904) injected ink in pig embryos and observed a subcutaneous network of 
lymphatic vessels. Through a long series of these ink injections, Florence R. Sabin traced 
back the lymphatic vessels to tiny buds close to the veins [26,27]( Figure 5B). Based on these 
observations she laid down the first theory for lymph vessel development[28,29]. According 
to Sabin, the lymphatic system develops from lymphatic primitive sacs, which are formed by 
sprouts from the venous system.  In this centrifugal theory, the neck and the head lymphatic 
endothelial cells sprout from the jugular sac and spread centrifugally into the surrounding 
tissues and organs where local capillaries form. Another theory (termed centripetal) proposed 
by McClure and Huntington (1908-1910) claims that lymphatic endothelial cells arise de 
novo from undifferentiated mesenchymal cells or circulating precursor cells[30]. According 
to this theory, initial lymphatic sacs arise in the mesenchyme independent of the veins and 
secondarily establish venous connections (3). Most of the experimental evidence for the non-
endothelial theory derives from experimental studies using xenopus and chick models[31]. 
However, recent studies in mice by Wilting et al have shown that non-endothelial precursor 
cells contribute to lymphatic sac formation[32]. Despite these findings it is still unknown to 
what extent the non-endothelial precursors contribute to lymphatic vessel development. Thus, 
embryonic lymphatic vessel might have a dual origin: endothelial and mesenchymal (figure 
4).  
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Figure 4. Large embryonic veins are suggested to be a mayor source for lymphatic endothelial cells.  Vein 
endothelial cells commit into lymphatic cells and form embryonic lymphatic sacs, which sprout and form 
primitive lymphatic plexus. Other non-endothelial sources such as mesenchymal cells have been also suggested 
to contribute to lymphatic vessel formation.  
 
In 1966, Lark and Burke determined the morphological difference between lymphatics and 
blood vessels and the first successful attempt to isolate lymphatic endothelial cells was carried 
out[33]. It was a hard task since no specific lymphatic endothelial markers were available at 
that time. Decades passed and specific endothelial markers such as prospero homeo domain -1 
(PROX-1), lymphatic endothelial hyaluronan receptor (LYVE-1), Podoplanin, VEGFR-3 
were discovered. The discovery of these specific lymphatic endothelial markers has 
contributed to the elucidation of some of the mechanisms behind lymph vessel formation and 
their implication in pathological conditions such as cancer, inflammation, psoriasis and 
asthma[34].  
 
Figure 5. A)‘Milky veins in dogs’, drawing by Gasparo Aselli (1627), cartoon adopted from Nature. .B) 
Florence R. Sabin (1904), drawing of proposed lymphatic vessel formation in pig embryos C) Experimental 
studies of VEGF-C-/- deficient mice and its role in lymphatic vessel formation. 
 
 12 
1.1.6 Lymphangiogenesis, molecular view of the centrifugal theory  
Lymphatic vessel formation is believed to start in mid-gestation, after the establishment of the 
cardiovascular system. On approximately E9.5-10.0 venous endothelial cells from the anterior 
cardinal vein start to express LYVE-1 [35]. Following this initial step, a polarized subset of 
LYVE-1 positive competent venous endothelial cells commence to express PROX-1 [36,37]. 
The induction of these lymphatic markers is believed to be triggered by unidentified signals 
from the surrounding mesenchyme. PROX-1 is considered to be a key component in the 
commitment program into lymphatic endothelial cells. Forced expression of this transcription 
factor in BECs leads to up-regulation of LEC specific markers[38]. PROX-1 induction is also 
speculated to be initiated by the large vein remodelling events that take place between E9.5 
and E13.5[39]. The vascular endothelial growth factor receptor 3 (VEGFR-3) is expressed 
after E8.5 in developing venous endothelial cells. As development progresses, VEGFR-3 
expression becomes primary confined to the lymphatic endothelium [23]. At E10-E11 the 
VEGFR-3 ligand, vascular endothelial growth factor C (VEGF-C), is released by nearby 
mesenchyme cells and induces budding off from the cardinal vein, migration and proliferation 
of the committed LECs [20]. In PROX-1 null embryos the budding off is arrested, resulting in 
embryos lacking lymphatic vasculature [37].  The induced migration of the committed 
PROX-1 positive cells is believed to be mediated by VEGFR-3. During the migration of the 
committed cells, expression of other LECs marker such as Podoplanin and neurophilin-2 is 
upregulated. PDPN-deficient mice die at birth due to respiratory failure and showed groove 
defects in the lymphatic vasculature [40].  The migration of the committed LEC leads to the 
formation of primitive lymphatic sacs.  During the lymph sac formation processes, BECs 
markers such as C34 and laminin are down regulated[35]. Further sprouting at E11.5-E14.5 
from the primitive sacs leads to the formation of the primary lymphatic plexus, which spreads 
throughout the head, neck, thorax and forelimbs. Later on after the formation of the jugular 
lymphatic sacs, lymphatic sac development also occurs in the posterior part of the embryo 
from local abdominal veins. These sacs sprout and subsequently penetrate surrounding 
interstitial tissues. 
 
1.1.7 Kidney vascular development 
The mammalian kidney is a highly intricate organ involved in many important physiological 
functions such as waste clearance, pH regulation, blood pressure regulation, and hormone 
production. It is also affected by a variety of live threatening pathologies such as diabetic 
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nephropathy and renal cell carcinoma. This fascinating organ is highly vascularized and 
receives a significant portion of the cardiac input. The permanent mammalian kidney, the 
metanephros is formed by delicate interactions of three different cells lineages: the epithelium 
of Wolffian-duct derived ureter, the mesenchyme of the nephric blastema giving rise to the 
secretory nephron and the endothelial cell lineage providing the vascular supply of the 
kidney[41]. These cell interactions are modulated by a fine tuned orchestra of growth factors. 
Among these factors VEGFA seems to play a critical role in renal development by promoting 
endothelial cell differentiation, capillary formation and proliferation of tubular epithelial 
cells[42].  
The murine kidney blood vasculature development begins right after the initiation of 
metanephroe formation at approximately E11.5, when endothelial cells from the embryonic 
aorta sprout and invade the developing kidney (angiogenesis) [31]. However it has been 
shown that developing kidneys also contain endogenous blood endothelial cells progenitors, 
which contribute to kidney microvasculature formation (vasculogenesis). These progenitors 
are observed in avascular areas of the developing kidney and are speculated to be of 
mesenchymal and epithelial origin [43]. In summary and according to experimental evidence, 
vasculogenesis and angiogenesis are potential mechanisms for local vessel formation in the 
developing kidney.  
During embryonic development, organ lymphatic vasculature is believed to originate 
from LECs sprouting from nearby extra lymphatic plexus[44], [29]. Lymphatic vessel 
formation and function in highly vascularized organs such as the kidneys has received little 
attention and the mechanisms behind lymphatic vessel formation and its implication in kidney 
function are still obscure. It is also unclear if individual organs like the kidneys contain other 
non-endothelial precursor cells that may contribute to in-situ lymphatic formation. 
Knowledge of renal lymphatic function and its implication in renal diseases is limited. The 
understanding of renal lymphatic formation will hopefully give us new and valuable insights, 
which may help us to develop new strategies to combat kidney diseases.  
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Part II 
1.2   Oncogene induced apoptosis and cellular senescence 
 
1.2.1 The cell cycle 
There are around 210 different cell types and about 75 trillion cells in the human body. All 
these cell types arise by cell division /multiplication from one single cell, the fertilized egg.  
Cell division is therefore a fundamental process for life. This process ensures the 
development and replacement of dead and old cells in every organ of the human body. From 
skin to liver tissues, cell division guaranties the wellness of each different organ of the body.  
Cell division is governed by the cell cycle, also named the cell division cycle. The cell cycle 
is well conserved among eukaryotes and it is composed by a serial of events leading to DNA 
replication and cell division. The mammalian cell cycle is activated by mitogenic signals and 
is composed of different and well-defined phases: the G1 (gap 1), S (synthesis), G2 (gap 2) and 
M (mitosis) phases of the cell cycle. In addition, the resting, quiescent state of a cell is 
referred to as G0.  The interphase is a common name for G1, S and G2. In this phase the cell is 
growing and preparing for mitosis by the accumulation of essential cell constituents and the 
replication of the DNA.  In the G1 phase external mitogenic and anti mitogenic signals dictate 
whether the cell should proceed to S phase, enter quiescence, go into a state of cellular 
senescence (see further section 1.3.4 on cellular senescence) and/or differentiate. Upon 
mitogenic signals the cell cycle starts by the initiation of synthesis of macromolecules such as 
RNA and proteins. If the cell decides to pursue with the cycle, in the next step, the S phase, 
the DNA is replicated. The main goal of this process is to create an identical copy of the 
entire genome. After the S phase the cell enters into the following second gap G2 phase 
during which growth and preparation for cell division occurs.  In the following mitosis phase 
(M), nuclear division takes place followed by the division of the cytoplasm, which allows the 
formation of two new cells [45].  
 
The cell cycle is controlled by different checkpoints that ensure the fidelity of cell 
division.  One of the major functions of the cell division checkpoints is to assess DNA 
damage. When DNA damage is found, the cell cycle is arrested or delayed and an attempt to 
repair the damage is initiated. If the DNA damage is irreparable the cell is target for 
destruction via apoptosis. There are at least 3 main cell division checkpoints, G1 (restriction) 
 15 
check point, G2 checkpoint and the metaphase checkpoint. The G1 check point is found at the 
end of the G1 phase of the cell cycle, right before the entry into S phase. In this checkpoint 
growth factor/anti-growth signals decide whether the cell should continue cell cycle 
progression, delay division or enter the G0 phase. The G2 checkpoint is located at the end of 
G2 phase and controls the start of the M phase. In the M phase, the proper chromosome 
segregation is controlled by the spindle assembly checkpoint (SAC). There are other less 
unknown check points found in the cell cycle and these cover other aspects in the complex 
progression of the cell cycle. The cell cycle checkpoints are of great importance for cell 
function and therefore highly relevant for tumor development [45]. 
  
1.2.2 Cyclin dependent kinases and the cell cycle  
The cell cycle is driven by oscillations in the activities of cyclin-dependent kinases (CDKs), 
which are activated by protein subunits called cyclins. CDK activity is tightly regulated by 
periodic synthesis and degradation of cyclins, cyclin kinase inhibitors and by reversible 
phosphorylation. There are at least 13 loci in humans encoding for CDKs and 25 loci 
encoding for cyclins respectively [46].  Among the different CDKs there are only 4 CDKs 
that actively take part in the cell cycle, CDK1 or CDC2, CDK2, CDK4 and CDK6 and ten 
cyclins belonging to four different groups (A, B, D and E) [47].  These different cyclins are 
specific for each specific phase of the cell cycle, where they accumulate and activate their 
CDK interacting partner.  Different CDK-cyclin complexes are involved in the regulation of 
the different cell cycle transitions: D type cyclins (D1, D2 and D3) together with CDK4 and 
CDK6 for G1 phase progression, E type cyclins (E1 and E2) with CDK2 for G1-S- 
transitions, A type cyclins (A1 and A2) with CDK2 for S phase progression, and B type 
cyclins (B1 and B2) with CDK1 complexes for entry into M phase[47]. Upon mitogenic 
signals mediated by different signaling pathways the cell cycle machinery is stimulated to 
start cell division by leaving the G0 resting phase.  In early G1 phase and upon stimulation by 
several mitogenic cascades including the Ras/Raf-1/Mek/ERK and β-catenin-Tcf/LEF 
pathways, D type cyclins (D1, D2 and D3) are induced and associate with CDK4 and CDK6 
to form cyclin D/CDK4 or 6 complexes. The formed CDK4/6-cyclin-D complexes partially 
phosphorylate and contribute to inactivation of the pocket proteins Retinoblastoma (Rb), p107 
and p103. The partial inactivation of Rb allows the expression of E type cyclins (E1and E2), 
which in turn associates with CDK2.  The formed CDK2-cyclin E complexes contribute 
further to the phosphorylation and inactivation of Rb. Normally in its hypo-phosphorylated 
(active) form, pRb acts a tumor suppressor by inhibiting cell cycle progression. Inactive Rb 
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dissociates from the E2F transcription factor thus allowing the activation of the E2F-1-
mediated transcription of genes involved in nucleotide metabolism, DNA synthesis and 
additional processes required for the S phase.  Cyclin A is expressed in the S phase and 
associates with CDK2 to form cyclin-A-CDK2 complexes which continues to phosphorylate 
Rb. Cyclin B is induced during the G2 and the M phase of the cell cycle where it binds to 
CDK1.  The formed CDK1-cyclin B complex mediates the onset of mitosis by inducing the 
nuclear envelope breakdown and the initiation of the prophase. Cyclin B is degraded by the 
APC E3 ubiquitin ligase complex at the metaphase-anaphase transition, which is required for 
exit from the M phase[45,47]. 
 
Mouse genetic studies have shown that CDK2, CDK4 and CDK6 are non-essential for 
the mammalian cell cycle [46,48,49]. Instead it seems that only CDK1 is crucial for proper 
cell cycle progression[50,51]. Embryos lacking all the interphase CDKs had a normal 
organogenesis and developed to midgestation. Interestingly, CDK1 interacts with all cyclins 
resulting in Rb hyperphosphorylation and the subsequent expression of genes that are 
regulated nu E2F transcription factors. Mice lacking CDK2 are viable and showed a survival 
of 2 years of age, thus indicating that CDK2 is not essential for proliferation and survival of 
most type of cells. However, CDK2 seems to be required for the completion of prophase I 
during meiotic cell division in male and female germ cells [52].  
 
The activity of the formed CDK/cyclin complexes is tightly regulated during the cell 
cycle progression. Beside the control of the cell cycle by the fluctuation of cyclin levels, there 
are other several layers of control that modulates the activity of cyclin-CDKs complexes. 
There are seven known proteins that prevent cell cycle progression by inhibition of the cyclin-
CDK complexes.  The INK4 proteins (Inhibitors of CDK4), p16
INK4A
, p15
INK4B
, p18
INK4C
 and 
p19
IN4D
 specifically targets CDK4 and CDK6 complexes. These CKIs have no effect on 
CDK2 and CDK1 complexes. The other CKIs, p21
Cip1
, p27
Kip1
 and p27
Kip2
 primarily inhibit 
CDK2 and CDK1 complexes, but are able to bind and regulate all cell cycle CDK 
complexes[45]. 
 
Cellular stress originated from DNA damage results in the induction and activation of 
p53, which in turn activates p21.  Growth inhibitory signals derived from anti-mitogenic 
factors such as TGFβ induces the activation of p27 and the subsequent arrest of the cell cycle. 
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The second family of CKIs is the INK4a/ARF family and includes the gene products 
p16INK4a and p19ARF. Activated p16 binds to CDK4 and arrest the cell cycle in G1 phase.  
p19ARF activation results in the stabilization of the tumor suppressor p53[45]. 
 
Extracellular anti-proliferative signals in the form of TGF beta can arrest the cell cycle 
by a rapid and strong transcriptional induction of p15 INK4B, which in turn blocks the 
formation and the already formed cyclin D-CDK4 complexes.  p15INKB1 mRNA levels in 
human keratinocytes are drastically elevated after exposure to TGFβ. TGFβ is also a weak 
inducer of the more widely acting p21 which can block the action of the remaining cyclin-
CDK complexes.  Stress signals such as DNA damage are potent inducers of p21 but in a p53 
dependent manner.  Mitogenic signals such as those mediated by P13K lead to the 
phosphorylation of the nuclear p21Cip1. Akt/PKB phosphorylates p21 in the nucleus causing 
it translocation to the cytoplasm where p21 cannot not longer block cyclin-CDK complexes 
[45].  
 
Cyclins are tightly regulated at different levels, and deregulated cyclins are often 
observed in cancer.  For example, cyclin E, the crucial activator of CDK2, is often 
deregulated in carcinomas, lymphomas and sarcomas [53]. D type cyclins are also deregulated 
in several cancers including carcinomas, melanomas and hepatomas [45,54]. CDKs are highly 
involved in tumor progression and emerging evidence from different studies suggest that 
depending on the cellular context tumor cells have specific requirements for individual CDKs. 
CDK4 has been implicated in Ras-mediated transformation. CDK4-null mouse embryonic 
fibroblasts showed resistance to response to Ras activation and the disruption of CDK4 in this 
setting led to senescence that was ARF/p53 independent [55].  CDK4 has been shown to be 
dispensable for mammary gland development, but is needed for the development of mammary 
gland tumors initiated by different oncogenes including HRAS and MYC [56]. Recently, 
CDK2 was implicated MYC repression of Ras induced senescence in rat embryonic fibroblast 
[57]. Additionally, CDK2 was also involved in MYC induction of cellular senescence. Loss 
of CDK2 enhances MYC induced senescence in pancreatic B cell tumors and improves the 
survival of mice bearing lymphoma [58].   The specific requirement for the different CDKs in 
tumor cells gives an excellent opportunity to elaborate novel strategies against cancer.  
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1.3 Safe guard mechanisms 
 
1.3.1 Apoptosis 
Apoptosis or programmed cell dead is a genetically controlled mechanism of cell death 
involved in the regulation of tissue homeostasis. Apoptosis plays an important role in 
development and in several pathologies including cancer. Apoptosis is often deregulated in 
incipient cancer cells.  During normal morphogenesis apoptosis sculpts the developing organs 
by removing cells that are no longer biologically necessary.  Genetic modified mice lacking 
key components of apoptosis showed developmental defects such as excess of neurons in the 
brain, facial abnormalities, delayed destruction of the webbing between the fingers and 
abnormalities in the palate and lens (ref biology of cancer) Apoptosis also is a crucial event in 
normal tissue physiology. For example apoptosis continually eliminates the epithelial cells in 
the villi of the small intestine. These cells are eliminate after four to five day journey from the 
bottom to the intestinal crypts to the tips of the villi [59]. 
 
The apoptosis program guaranties the death of the cells by a cascade of well-
coordinated events.  The cellular events leading to cell death start with the formation of blebs 
in the plasma membrane followed by the collapse of the nucleus into a dense structure. This 
dense structure is then fragmented as the chromosomal DNA is cleaved into small fragments. 
Ultimately the apoptotic cell breaks up into small fragments called the apoptotic bodies.  
These bodies are often removed by neighboring cells and circulating macrophages [59].  
 
Apoptosis can be triggered by several stimuli including growth factor deprivation, 
hormones and cytokines, radiation, toxins, hypoxia, etc. Moreover, aberrant oncogene 
expression is also known to induce apoptosis [59]. Two main pathways trigger the complex 
apoptosis program:  the extrinsic or death receptor pathway and the intrinsic or mitochondrial 
pathway. Characteristic for these two apoptotic pathways is the activation of a family of 
cysteine proteases called caspases.   In addition to these two pathways the perforin/granzyme 
pathway can also induce apoptosis. Each one of these pathways is triggered by specific 
signals that stimulate an energy dependent cascade of molecular events. All these 3 pathways 
converge in the same execution pathway in which caspase 3 is cleavage resulting in DNA 
fragmentation, degradation of cytoskeletal and nuclear proteins, cross-linking of proteins, 
formation of apoptotic bodies, expression of ligands for phagocyte cell receptors [60]. 
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1.3.2 The extrinsic pathway or death receptor mediated pathway  
The extrinsic pathway conveys apoptotic messages via transmembrane receptor-mediated 
interactions [61]. The transmembrane receptors mediating these interactions are members of 
the tumor necrosis factor (TNF) receptor gene superfamily and are usually called the death 
receptors ( i.e., Fas, also called CD95/Apo-1; TNF receptors; TRAIL receptors) [62,63].  
These members of the TNF receptor family share similar cysteine-rich extracellular domains 
and have a cytoplasmic domain called the death domain. The best characterized ligands for 
these death receptors are FasL, TNF-A, Apo3L, Apo2L. Upon ligand binding the intracellular 
domains of the death receptors aggregate and cytoplasmic adapter proteins are recruited 
[64,65,66,67].  For example, FasL binding to its receptor Fas results in the binding of the 
adapter protein Fas associated dead domain (FADD) and binding of the TNF ligands to the 
TNF receptor triggers the binding of the adapter protein TNF associated dead domain 
(TRADD) with the recruitment of FADD and TRIP[68,69].  Procaspase -8 then binds to 
FADD and form the death inducing signaling complex (DISC) that in turn activates the 
autocatalytic function of procaspase 8 [70]. The activation of procaspase-8 in the DISC 
triggers a cascade of caspase activity that leads to cell death. The extrinsic pathway is 
inhibited by a protease-deficient caspase homolog, FLICE-inhibitory protein (FLIP). This 
protease-deficient caspase is highly homologous with procaspase 8 and is also recruited to the 
DISC but his role is controversial. FLIP is known to bind and inhibit FADD and caspase-8 
[71,72,73].  However, it has been suggested that physiological levels of FLIP might induce 
apoptosis. 
 
1.3.3 The intrinsic or mitochondrial pathway 
The intrinsic pathway for programmed cell death is characterized by non-receptor mediated 
intracellular signaling that perturbs the status of the mitochondria and initiates apoptosis.  
This signaling pathway is induced by different stress stimuli including DNA damage and 
oncogene activation [61].  The different stress stimuli cause changes in the inner 
mitochondrial membrane resulting in loss of the mitochondrial transmembrane potential and 
release of two groups of sequestered pro-apoptotic proteins into the cytosol.  The first 
released group of sequestered proteins is composed by cytochrome c, Smac/Diablo, and the 
serine protease HtrA/Omi [74,75]. These released proteins induce the caspase-dependent 
mitochondrial pathway.  Cytochrome c binds to the cytosolic protein Apaf-1 as well as 
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procaspase-9 facilitating the formation of the apoptosome [76,77]. The formation of this 
complex is believed to be the point of no return, and apoptosis will occur. Smac and/DIABLO 
and HtrA2/Omi are believed to contribute to apoptosis by the inhibition of IAP (inhibitors of 
apoptosis proteins) activity [78,79]. The second pool of pro-apoptotic proteins being released 
into the cytosol are AIF, endonuclease G and CAD. The release of this group of pro-apoptotic 
proteins is a late event and occurs when the cell is committed to die. AIF, endonuclease G 
(endoG) and CAD are translocated to the cell nucleus where they aid DNA fragmentation and 
condensation of nuclear chromatin[80]. Once in the nucleus AIF causes DNA fragmentation 
into approximately 50 to 300 kb pieces and condensation of peripheral chromatin (Stage I 
condensation)[81]. Nuclear translocated endoG cleaves chromatin DNA into nucleosomal 
fragments [82].  Both IAF and endoG cleaves chromatin independently of caspases. Therefore 
these nucleases represent a caspase-independent apoptotic pathway initiated from the 
mitochondria.  CAD in turn is cleaved by caspase -3 in the nucleus and induces 
oligonucleosomal DNA fragmentation and more advanced chromatin condensation (Stage II 
condensation) [81]. 
 
Members of the Bcl-2 family of proteins and the tumor suppressor protein p53 regulate 
the intrinsic pathway of apoptosis [59].  Pro and anti- apoptotic members compose the Bcl-1 
family. The anti apoptotic protein members include the Bcl-2, Bcl-xl, Bcl-xs, Bcl-w and 
BAG. The pro-apoptotic members include Bcl-10, Bax, Bak, Bid, Bad, Bim, Bik and Blk. p53 
is a critical regulator of these proteins and its suggested that the main mechanism of action of 
the Bcl-2 family of proteins is the regulation of cytochrome c release from the mitochondria 
by alteration of mitochondrial membrane permeability [61]. 
 
1.3.4   Cellular senescence 
Cellular senescence is a mechanism that prevents cells to divide indefinitely. This 
phenomenon was first described decades a go by Hayflick and colleagues in human 
fibroblasts. Hayflick cultured these cells under conditions that enhanced a continuous cell 
replication.  After a number of finite cellular divisions (known as the Hayflick effect) these 
cells lost their replicative potential (replicative senescence) [83,84]. Senescent cell are 
characterized by the inability to progress though the cell cycle despite mitogenic stimulation.  
In contrast to quiescence, the observed growth arrest in senescent cells is persistent. In spite 
the fact that these cells are growth arrested, senescent cells remain metabolically active. It has 
been suggested that senescence plays an important role in regulating aging and tissue 
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homeostasis. In addition, several data have pinpointed cellular senescence as another 
important barrier against tumor cell transformation [85]. Apart from irreversible cell cycle 
arrest, senescent cell are characterized by altered morphology. Senescent cells are often large 
and flattened out. Further, cells undergoing cellular senescence exhibit senescence-associated 
beta-galactosidase (SA-b-gal) activity due to increased lysosomal activity and often display so 
called senescence-associated heterochromatin foci (SAHF) characterized by for instance 
increased trimethylation of histone 3 at lysine 9 (H3K9me
3
)[86,87]. Senescent cells also 
display a specific gene expression patterns, including senescence-associated secretory 
phenotype (SASP) which involves the production of factors that reinforce the senescence 
arrest, alter the microenvironment, and trigger immune   surveillance of the senescent cells 
[88,89,90,91].   
 
1.3.5 Replicative senescence 
The main cause of the replicative senescence described by Hayflick et al is attributed to 
telomere dysfunction. Telomeres consist of tandem non-coding DNA repeats (TTAGGG) and 
the principal function of these repeats is to cap the chromosomes.  After each cell division 
telomeres in human cells are shortened due to the end replication problem of DNA 
polymerase and the suppression of telomerase expression.  For example normal human 
diploid fibroblast shorten their telomeres with 50-100 base pairs after each cell division. In 
order to compensate for telomere shortening, mammalian cells express an enzyme called 
telomerase.  This ribonucleoprotein has two major components: an enzymatic telomerase 
reverse transcriptase catalytic subunit, hTERT and an RNA component (hTR or hTERC) [92]. 
After reaching a critical telomeric length and loosing the cap, the telomere ends are 
recognized as DNA damage and induces DNA damage checkpoints.  Two different check 
points have been identified that limits proliferation in response to telomere dysfunction: the 
first mortality stage (M1) and the second mortality stage (M2) also called crisis stage. The M1 
is characterized by permanent cell cycle arrest and depends on p53 activation. Normally 
human fibroblasts undergo replicative senescence after 50-70 divisions. Cells with 
dysfunctional p53 bypass the senescence barrier and continue to proliferate independent of the 
critical length of the telomeres.  Further shortening of the telomeres induces the M2 
checkpoint, which is p53 independent and is characterized by extensive chromosomal 
instability and cell death [93]. In contrast to normal human cells where telomere shorting 
occurs as an anti proliferative mechanism, cancer cells maintain their telomere length by 
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overexpression of telomerase or by a mechanism known as alternative lengthening of 
telomeres. 
 
1.3.6 Premature and oncogene-induced senescence  
Experimental evidence from in vitro and in vivo studies have suggested that in addition to 
replicative senescence, cellular senescence can be induced prematurely by diverse stimuli 
including dysfunctional non-telomeric DNA damage, activated oncogenes, (oncogene induced 
senescence, OIS), oxidative stress and different agent causing DNA damage[85]. This is an 
important mechanism to suppress tumorigenesis by preventing proliferation of cells at risk for 
neoplastic transformation. For instance in primary cells, potent oncogenes  such as RAS 
initially acts as strong mitogenic factor via the  mitogen-activated protein kinase (MAPK) and 
the phosphatidylinositol kinase (P13K)  cascade. However RAS eventually induces premature 
senescence via the p53 and P16 (INK4A) pathways [94].  These two pathways are believed to 
establish and maintain the growth arrest caused by senescent signals. Activation of the MAPK 
kinase pathway by RAS ultimately leads to the induction of expression of the alternate-
reading-frame protein ARF, which stabilizes p53 by antagonizing the activity of the E3 
ubiquitin-protein ligase HDM2 (MDM2 in mice) [95]. Stabilized p53 establish the senescence 
growth arrest in part by inducing the CDK inhibitor p21. This kinase inhibitor in turn prevents 
CDK2-mediated phosphorylation and inactivation of pRB. Senescence signaling also engages 
the p16-pRb pathway. This pathway is characterized by the induction of the CDK inhibitor 
p16, which also prevents pRB phosphorylation and inactivation by inhibiting CDK4/6.  pRB  
in turn stops the cell cycle and promotes senescence by suppressing the activity of the E2F 
transcription factor. As discussed in the cell cycle section, E2F is required for the stimulation 
of genes needed for cell cycle progression. It has been shown that E2F it self induces ARF 
expression and the subsequent p53 activation [96]. 
 
The early stages of tumor progression are characterized by unbalanced cell cycle and 
deregulated oncogenes. The combination of loss control of the cell cycle and oncogene stress 
results in aberrant DNA replication with stalled replication forks, which in turn triggers the 
DNA damage response (DDR).  This response includes the activation of ATM and CHK2 
kinases, which phosphorylate and augmentation the activity of the tumor suppressor p53.  
DNA damage induced by carcinogens, cancer drugs, irradiation or oncogene-induced 
replication stress or oxidative damage thereby at least in part induce senescence via 
accumulation and activation of p53, which promotes cellular senescence or apoptosis, as 
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mentioned above [59]. 
 
1.3.7 The MYC proto-oncogene 
The MYC oncogene family, including MYC (c-myc), MYCN (N-myc) and MYCL (L-myc) 
regulates several normal cellular processes such as cell growth, cell division, metabolism, 
differentiation, stem cell function, apoptosis, senescence and angiogenesis. This family of 
potent proto-oncogenes is also highly involved in the development of many human 
cancers. Deregulated MYC expression caused by various types of genetic insults leads to 
constitutive MYC activity in a variety of cancers and promotes oncogenesis [97]. For instance 
rearrangements of the MYC family loci by amplifications or translocations are often observed 
in several types of cancers. The most well known examples are the translocations of MYC 
located on the human chromosome 8 into the immunoglobulin loci in 100% of Burkitt´s 
lymphoma cases and the amplification of MYCN in 40% of advanced neuroblastomas. These 
genomic rearrangements are strongly connected to poor prognosis [98]. In fact MYC was first 
discovered in Burkitt’s lymphoma patients. The MYC proto-oncogenes encode DNA binding 
transcription factors that belong to the basic helix-loop-helix leucine zipper (bHLHZip) 
family. MYC heterodimerizes with its interaction partner Max and together they bind to 
specific DNA sequences termed E-boxes in promoters of the target genes.  The binding of the 
MYC-MAX heterodimer at E boxes activates transcription of target genes [99]. MYC is also 
in known to repress transcription by binging to other interaction partners including MYC 
interacting zinger protein 1 (Miz-1) [100].  MYC gene regulation is mainly achieved by 
recruiting transcriptional cofactors involved in modulation of RNA polymerase II function 
and of chromatin structure, including histone acetyl transferase (HAT) complexes [97]. 
The human MYC protein contains 439 amino acids with 150 amino-terminal residues 
comprising the transactivation domain (TD) that contains two conserved MYC family boxes I 
and II (MBI and MBII). In MBI two crucial residues for MYC function and stabilization are 
found, threonine 58 (T58) and serine 62 (S62). Phosphorylation of serine 62 by different 
kinases stabilizes MYC, while threonine 58 phosphorylation destabilizes MYC [101]. These 
two residues seem to be phosphorylated in an interdependent manner; phosphorylation of S62 
catalyzed by ERK kinases is a prerequisite for phosphorylation of T58 by GSK3β [102]. The 
carboxy-terminal 90 amino acids constitute the DNA binding and helix-loop-helix-leucine 
zipper dimerization domain (HLH-LZ) (Figure 6). This domain is essential for the binding to 
MYC obligate partner Max and for the transformation of primary and immortal cells [97].   
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Figure 6. MYC oncoprotein domains. MBI: MYC box I, MBII: MYC box 2, NLS: nuclear localization 
signal, B: basic region, HLH: helix-loop-helix motif, LZ: leucine zipper motif.  
 
The MYC protein is believed to regulate about 10-15% of the genes in the genome and 
like other crucial key regulators of the cell the expression and activity of MYC are tightly 
regulated at multiple levels. In fact MYC has a very short half-life and it’s directed to 
proteasomal degradation through the ubiquitin pathway.  In this regulatory pathway, the small 
and highly conserved polypeptide ubiquitin is covalently conjugated to lysine residues of the 
target proteins by the combined action of at least three enzymes: the ubiquitin-activating 
enzyme (E1), an ubiquitin-conjugating enzyme (E2), and an ubiquitin-protein ligase (E3). 
Attachment of poly-ubiquitin chains to target proteins leads to recognition by the activated 
26S proteasome and rapid degradation. MYC ubiquitylation is mediated by at least three 
different E3 ligases, SCFFbw7, SCFSkp2 and HectH9 [103].  Fbw7 a component of the SCFFbw7 
ubiquitin ligase and tumor suppressor associates with MYC and promotes its turnover by 
proteasomal degradation.  Phosphorylation of MYC at T58 by glycogen synthase kinase 3β 
(GSK3β) seems to be required for Fbw7 recognition and ubiquitylation of MYC 
[104,105,106].  The importance of the T58 residue in regulating MYC stability   is 
highlighted by the fact that the T58 residue is often mutated in a subset of Burkitt’s 
lymphomas [105]. 
 
 
1.3.8 MYC cellular function 
Cellular growth is prerequisite for subsequent cell division and in order to achieve cell 
division, the cell has to be stimulated by mitogenic signals followed by cellular growth 
through the synthesis of new cell components. MYC is known to be a master regulator of cell 
growth and proliferation. Endogenous MYC is activated trough different cellular stimuli and 
leads to the transcription of a spectrum of target genes that regulate the cell cycle and 
carbohydrate and nucleotide metabolism, as well as ribosomal and mitochondrial biogenesis. 
MYC expression is induced by several mitogenic pathways including Wnt, Notch, STAT, 
receptor tyrosine kinases (RTKs) such as platelet-derived growth factor receptor (PDGFR), 
epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor (IGFR), as 
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well as hormone receptor pathways [97] (Larsson).  These pathways are often upregulated 
during cell transformation and leads to aberrant MYC activation. By stimulating the 
transcription of all three RNA polymerases (RNA Pol I, II and III), MYC coordinates the 
process of rRNA transcription and processing, ribosomal protein transcription and translation, 
and translation initiation [97].  MYC has also been linked to energy metabolism through its 
regulation of glycolysis.  Under normal condition mammalian cells uses oxygen to convert 
glucose energy via oxidative phosphorylation in the Krebs cycle, unlike cancer cells that rely 
on glycolysis for the generation of energy and are less dependent on oxygen, a phenomenon 
called the Warburg effect [107]. MYC stimulates glucose uptake and glycolysis by regulation 
of genes encoding GLUT1, phosphofructokinase and enolase [108]. The increase of glucose 
uptake and the upregulation of other glycolytic genes lead to the formation of lactate even 
under aerobic conditions.  Nevertheless, MYC is also involved in mitochondrial biogenesis 
and energy production by oxidative phosphorylation. Activated MYC is involved in the direct 
regulation of nuclear genes controlling mitochondrial mass, structure and function [97,109].   
 
In addition to regulating cell growth, metabolism and protein synthesis, MYC plays an 
important role in cell cycle regulation by regulating genes involved in cell cycle progression, 
such as cyclins, cyclin-dependent kinases (CDK), Cdk inhibitors (CKI), E3 ubiquitin ligase 
components targeting CKIs and replication proteins [97]. Moreover, MYC also has been 
directly implicated in the control of DNA replication. Over expression of MYC in 
mammalian cells causes increased replication origin activity subsequent DNA damage and 
check point activation [110]. MYC is also highly involved in stem cell self renewal and 
differentiation. Recently MYC was shown together with OCT4, SOX2, NANOG to be 
required for reprogramming of primary somatic fibroblast (iPS) [111,112]. 
 
MYC is a strong inducer of apoptosis and its up-regulation induces apoptosis by 
induction of p19Arf, which in turn stabilizes the tumor suppressor p53 [113], and by 
suppressing the anti-apoptotic genes BCL2 and BCL-xL and genes involved in the main 
apoptotic pathways. The tumor suppressor p53 is often mutated during the progression of 
MYC induced tumors and targeted deletion of p53 in the Eµ-myc transgenic mice model 
hastens MYC induced B lymphoma development [114].  
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Recently different reports have shown that MYC overexpression not only triggers apoptosis 
but can also induce cellular senescence under certain conditions. Loss of CDK2 together with 
ectopic MYC expression sensitized mouse embryonic fibroblast  (MEFs) to senescence, 
increased senescence in pancreatic B-cell tumors and delayed the onset of MYC-driven 
lymphoma [58]. Similarly, loss of the Werner gene (WRN) also induces senescence under 
conditions of MYC overexpression [115]. However, in contrast to many other oncogenes such 
as RAS and BRAF, MYC usually acts as a suppressor of senescence [116,117,118].  We 
recently demonstrated that suppression of RAS-induced senescence by MYC in rat embryonic 
fibroblasts (REFs) is associated with CDK2 activity and requires phosphorylation of MYC at 
Ser- 62 by CDK2 [57]. Loss of CDK2 therefore seems to switch MYC from a suppressor to 
an inducer of senescence (Figure 7) [119,120] 
               
Figure 7. MYC induction/repression of senescence. Loss of CDK2 and overexpression of MYC induce 
senescence.  MYC´s phosphorylation by CDK2 is crucial for MYC repression of Ras induced 
senescence 
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2.  AIMS of this study 
 
The content of this doctoral thesis work is divided into two parts. In the first part (paper I) we 
examined endothelial cell migration in response on stable gradients of VEGFA and the 
formation of lymphatic vessels in the developing mouse kidneys. Directed endothelial cell 
migration plays a central role in physiological and pathological angiogenesis. This complex 
process is governed by the interplay between gradients of growth factors and their receptors.  
The mechanisms behind the cell response to graded distributions of chemotactic factors are 
still poorly understood. In order to clarify the response of endothelial cells to stable 
chemotactic gradients, human umbilical vein endothelial cells (HUVECs) and human 
umbilical artery endothelial cells (HUAECs) were expose to stable hill- shaped gradients of 
VEGF and FGF2 using a microfluidic chemotaxis chamber (MCC) and time lapse 
microscopy. 
 
Lymphatic vessels are believed to develop from large embryonic veins and mesodermal 
cells. Lymphatic vasculature in the different organs is suggested to form via sprouting 
processes during development. Lymphatic vessel formation and function in highly 
vascularized organs such as the kidneys has received little attention and the mechanisms 
behind lymphatic vessel formation and its implication in kidney function are still obscure. 
Intrarenal lymphatics have been postulated to play an important role in the progression of 
renal diseases and transplantation. We therefore aimed to investigate lymphatic formation in 
the mouse embryonic kidney (paper II) . 
 
The general aim of the second part of this thesis was to clarify MYCs role in the 
induction of the safe guards mechanisms against tumor transformation. Deregulated MYC 
induces apoptosis, which is often overcome during tumor transformation. Moreover MYC has 
been proposed as a new regulator of oncogene-induced senescence.  In the first part of the 
second part (paper III) of this thesis, we aimed to address the importance of the extrinsic 
(death receptor-mediated) versus the intrinsic (mitochondrial) pathways of apoptosis in MYC 
driven transformation of HSCs.  In the second part (paper IV) we aimed to investigate 
whether pharmacological inhibition of CDK2 interferes with MYC-driven tumor development 
in vivo trough senescence.   
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3. Results and discussion 
 
3.1.1 Endothelial cell migration in stable gradients of growth factors (Paper I) 
In paper I, we used a microfluidic chemotaxis chamber (MCC) in order to clarify the response 
of HUVECs and HUAECs to shape graded chemotactic gradients. MCC were made of 
transparent PDMS in order to allow live imaging of the tested endothelial cell. The MCC was 
attached to culture dishes containing the mentioned endothelial cells.  We first tested the 
shape profiles of VEGFA165 by adding it together with FITC-dextran in the middle of the 
MCC reservoir. The shape profiles along the length axis of the chamber were tested by the 
measuring the fluorescence emitted by FITC-dextran.  The simulation of the shape profile 
with FICT-dextran and VEFGA165 showed that FITC-dextran profiles serve as a good 
approximation for the distribution of VEGFA165 in the MCC. Additional experiments were 
performed in order to test the effect of FITC dextran on the function of the tested VEGF165. 
These analyses showed that FITC-dextran did not interfere with the function of VEFG165. 
 
3.1.2 Migration of endothelial cells towards stable hill shapes of VEGFA165 (Paper I)   
We next tested primary endothelial cells isolated from artery (HUAECs) or vein (HUVECs) 
for migration. These cells attached well to gelatin-coated culture dishes after attachment of 
the MMC and exposure to flow rates between 60 and 2000 µm/s.  For the initial and 
subsequent measurements of migration, cells located in the middle and in the edges of the 
MCC were not include in the analysis. Individual endothelial cell migration was recorded by 
time lapse microscopy during 200 min. Cell migration activity was more efficient during the 
first hour of the running experiment and about 85% of the HUVECS located in the left of the 
CMM migrated toward the middle of the chamber and in higher concentration of VEGF165.  
Individual cell migration was scored using a polar plot where the starting point of all cells is 
assigned to the middle of the plot. In control experiments HUVECs migration towards the 
middle of the chamber was not observed in gradients devoid of VEFGF165.  In addition to 
HUVECS, arterial endothelial cells were also exposed to hill-shaped VEGF165 gradients.  
These cells also responded to the VEGF gradients and were attracted towards an increase in 
concentration of VEGF165. The above results suggest that endothelial cells from different 
vascular beds can migrate towards stable hill shaped VEGF65 gradients in the MCC. We also 
modulated the VEGFA-induced chemotaxis by gradually lowering the pump flow speed.  By 
stepwise lowering the pump shallower gradients were produced due to the increased diffusion 
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time of the growth factor molecules in the MCC.  HUVECs were exposed to hill-shape 
VGFE165 gradients (0-50ng/ml at the inlet) and to flow speeds between 60 and 200 um/s.  
Exposure to the these different created gradients reveled that the chemotactic response decline 
together with decreasing gradient steepness until it resembled random migration at 60 um/s.  
  
3.1.3 Chemotactic response of endothelial cells to stable gradients of the VEGFA121 
isoform (Paper I)  
VEGFA co-receptor binding also plays a crucial role in receptor activation and signaling. It 
has been shown that in developing tissues and in different cell signaling assays that 
proteoglycans co-receptors are needed for the proper distribution and activation of several 
VEGFA splice forms (ref). It is still unclear if VEGFA binding to HSPGs is strictly required 
for the target endothelial cell to interpret positional information provided by the gradient.  In 
order to clarify this, we generated gradients with VEGFA121 isoform. This VEGF isoform is 
unable to interact with proteoglycans and neurophilin co-receptors.  HUVEC exposed to 
stable hill-shaped gradients of VEGF121 (0-50 ng/ml) in the MCC showed increased 
migration and the positive chemotaxis induced by VEGFA121 was 22 ± 10 µm as compared 
with 45 ± 10 µm for VEGFA16 
 
3.1.4 Endothelial cell response to a gradient of FGF2 (Paper I) 
Many different cytokines are involved in the regulation of chemotactic endothelial cell 
migration during angiogenesis.  Together with VEGFA and the angiopoietins, FGF2 have 
been considered the major promoters of chemotactic endothelial cell migration.  Nearly all the 
experimental data concerning the chemotactic potential of FG2 on endothelial cells derive 
from studies using the Boyden chamber. Using our chamber and exposing the cell to a hill-
shape FGF2 gradient profile (0-50 ng/ml) equivalent to with the one tested for VEGFA did 
not significantly induce chemotaxis of HUAECS but had a small effect in HUVECs. Cell 
migration in response to FGF2 was also tested at different flow rates and the highest 
chemotactic response exhibited by HUVECs was seen in gradients ranging from 0 to 50 
ng/ml of FGF2 generated at a flow speed of 200 µm/s.  
 
3.1.5 Endothelial chemotactic responses in different regions of the gradients  (Paper I) 
The increased non-directional (chemokinesis) activity of HUVEC migration due to the effects 
of VEGFA and FGF2 were evaluated by analyzing total cell migration distances in the 
absence of growth factor, comparing with growth factor given either at constant concentration 
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of 50 ng/ml or in the form of a gradient (0-50ng/ml). Total migration of cell exposed to 
constant levels of VEGFA165 was considerably reduced compared to non-stimulated cells. 
Cell migration was promoted in cell exposed to a gradient of VEGF165 and the speed of 
migration was comparable with unstimulated cell. Constant concentration of VEGF165 
together with the absent of flow was shown to reduce chemokinesis. The VEGF121 isoform 
reduced chemokinesis and constants concentration of FGF2 (50ng/ml) gave a small increase 
in chemokinesis.  Different doses of VEGF and FGF2 effects on chemokinesis were analyzed 
and VEGFA but not FGF2 was shown to reduce chemokinesis at all tested concentrations. 
 
3.2 Lymphatic vessel formation in the developing mouse kidneys (Paper II)  
In order to explore renal lymphatic formation in a developing organ, embryonic kidneys were 
dissected from wild type mouse embryos between E.13.5 and E17.5 and immunostained for 
lymphatic and blood endothelial markers. Whole mounted kidney immunostainings revealed a 
well organized network of CD31 -positive blood vessels together with scattered cells 
expressing LYVE-1 in all analyzed time points.  At E16.5, lymphatic vessel-like structures of 
variable size positive for podoplanin, PROX-1, LYVE-1 and VEGFR-3 were observed 
adjacent to the renal ureteric pelvis.  At the following time point e.g. E17.5; two large LYVE-
1 positive vessels emerging from the ureteric bud region were found in renal pelvis and in the 
ventral renal cortex region. These LYVE-1 positive vessels followed large CD31 positive 
renal veins and branched in the renal cortex. 
 
3.2.1 Contribution of lymphatic precursors in the formation of renal lymphatic 
vasculature (PaperII) 
Recent studies have shown that during embryonic development PROX-1 positive macrophage 
like cells are involved in lymphatic sac formation[32]. Other studies also have implicated 
F4/80 positive macrophages in lymphatic vessel formation during wound healing 
processes[121]. Aiming to explore the contribution of lymphatic precursor cells in organ 
lymphatic vessel formation, we next analyzed the observed scattered single LYVE-1 positive 
cells for the expression of the pan macrophage marker F4/80 and PROX-1. A large fraction of 
the single cells expressing LYVE-1 was also shown to co-express F4/80.  However these 
double positive cells were never found to express PROX-1 or to be part of clearly identifiable 
lymphatic structures.  The observed LYVE-1 and F4/80 positive cells in E15.5 and E17.5 
time points were flow sorted and analyzed for the expression of VEGFC, VEGFR2, VEGFR3 
and PROX-1 transcripts. The flow sorted analysis showed subpopulations of cells expressing 
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both LYVE-1 and F4/80, these cell fractions also were relatively constant and around 0.5-1% 
of the total cells of embryonic kidney at E13.5 and E15.5. However at E7.5 the double 
positive population of cells increases to 3.5 % of all cells.  At this time point of kidney 
development the fraction of LYVE-1 positive cells also increased and it may reflect the 
observed invasion of lymphatic vessels into the kidney around E16.5-17.5. Transcript analysis 
of the flow-sorted fractions of kidney cells revealed that VEGFC expression was lower in 
LYVE-1 and F4/80 positive cells and in addition these cells were not expressing VEGFR-2 
and VEGFR-3. Thus suggesting that these cells may not respond to VEGFA and the pro-
lymphatic factor VEGFC.  PROX-1 transcript levels were highest in LYVE-1 positive cells at 
E15.5 and no significant up regulation of PROX-1 message was seen in F4/80 positive cells. 
LYVE-1 positive cells also expressed VEGFR-2, thus indicating their endothelial origin.  
 
3.2.2 Lymphatic vessel formation in embryonic renal explants  (Paper II) 
We next explored in-situ lymphatic vessel formation during kidney development. E13.5 
kidney explants were grown on filter discs and in collagen I, followed by VEGF-C and 
fibroblast growth factor (FGF-2) stimulation. In-situ lymphatic vessel formation was accessed 
by immunostaining for the lymphatic markers PROX-1, LYVE-1, podoplanin and CD31. The 
immunostainings revealed PROX-1 positive lymphatic vessel-like structure formation in the 
cortex of 3 days un-stimulated explants (figure 6A). However treatment with VEGFC and 
FGF2 increased the formation of lymphatic structures (Figure 6B and D). These lymphatic 
structures showed high expression of LYVE, podoplanin and PROX-1 and low expression of 
CD31 (Figure 6 B-C). In some areas of the kidneys, formed sprouts showed signs of BEC to 
LEC trans-differentiation.  Further analysis of the kidney explants after 3-4 days of culture, 
revealed the formation of PROX-1 clusters in the extended CD31 positive network.  
 
In conclusion lymphatic vessel formation during embryonic murine kidney development is 
mainly achieved by invasion of LECs. These cells might sprout from pre-existing lymphatic 
plexus and invade the kidney following the ureteric bud.  Once in the kidney cortex these 
large lymphatic vessels tend to branch into small vessel of different caliber. However when 
embryonic kidneys were dissected and cultured for three days in the presence of pro-
lymphatic factors, renal lymphatic precursor cells seem to be stimulated to transdifferentiate 
into LECS. These stimulated cells form lymphatic like structures that are positive for the 
commonly used lymphatic markers. Further studies are required to firmly establish whether 
transdifferentiation from BECs to LECs take place in the developing kidneys. 
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Result and Discussion part II 
 
3.3 In vivo impact of the intrinsic and the extrinsic pathways of apoptosis on MYC 
induced malignant transformation of HSCs (Paper III)  
MYC is known to be involved in the development of multiple human cancers including acute 
myeloid leukemia. Deregulated MYC is known to be a strong effector of the two main 
apoptotic pathways (intrinsic and extrinsic). This anti-tumorigenic capacity of MYC is often 
overcome during tumor progression by genetic lesions.  Mutations and deregulation of both 
the intrinsic and extrinsic apoptotic pathways have been found in AML. However, the relative 
contribution of these two pathways for the AML disease has not been investigated 
methodically. Aiming to study the effect of the anti-apoptotic genes products regulating the 
two apoptotic pathways on MYC driven transformation, HSCs were isolated from bone 
marrow and transduced with combinations of two different retroviruses:  one containing 
MYC-YFP and the other either BCL-XL (regulating the intrinsic apoptotic pathway) or FLIPL 
(regulating the extrinsic pathway) linked to GFP. The transduced HSCs were then 
transplanted into lethally irradiated syngeneic recipient mice. 
 
3.3.1 Blockade of the intrinsic but not of the extrinsic pathways of apoptosis hastens 
MYC driven tumorigenesis (Paper III).  
The myeloid and lymphoid cell populations of mice transplanted with HSCs transduced with 
MYC-YPF were efficiently reconstituted. However, 7-9 weeks after transplantation the mice 
started to display early sings of the disease. These included ruffed fur, wasting and slow 
movements that rapidly developed into hind limb paralysis within two days. The mice rapidly 
became terminally ill and were subsequently sacrificed. Necropsy analysis of these mice 
showed that the animals had enlarged spleen and liver, non-coagulating blood, spotted lungs, 
and in many animals also enlarged lymph nodes and thymus were observed. On the contrary 
to the MYC-YFP mice, control mice transplanted with HSCs transduced with Mock-YFP and 
Mock-GFP remained healthy during the whole duration of the study.  Mice transplanted with 
MYC-YFP showed a median survival of 56 days after HSCs transplantation.  We next 
examine the influence of the intrinsic pathway of apoptosis on MYC driven neoplasia. 
Isolated HSCs were transduced with a combination of MYC and BCL-XL, which blocks the 
intrinsic apoptosis pathway. These transduced cells were then transplanted into lethally 
irradiated mice. The MYC/BCL-XL transplanted mice became moribund 2 weeks after 
transplantation and had a median survival of 17 days. The mice also displayed similar sings of 
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the disease as the MYC-YFP mice; necropsy analysis of moribund mice showed that tumors 
were disseminated throughout the hematopoietic tissues with extensive involvement of spleen 
and bone marrow and tumor infiltration of the liver. These results clearly showed that 
inhibition of the intrinsic pathway of apoptosis accelerates MYC driven transformation..  We 
next tested if FLIPL, an inhibitor of the extrinsic apoptotic pathway, affects MYC driven 
tumorigenesis in HSCs. Bone marrow isolated HSc were co-transduced with retroviruses 
containing MYC-YFP and FLIPL-GFP and transplanted into irradiated mice. These MYC-
YPF/FLIPL-GFP mice showed similar kinetics and signs of the disease as the Mock-MYC 
mice. All the MYC/FLIPL mice became terminally ill within 9 weeks and had medial survival 
of 58 days. Autopsy of the MYC/FLIPL mice showed that these mice had similar pathological 
features as the Mock/MYC mice and these include enlarged spleen and liver, non-coagulating 
blood, spotted lungs and in many animals also enlarged lymph nodes and thymus.  In 
conclusion these results suggested that inhibition of the intrinsic but not the extrinsic 
pathways of apoptosis synergized with MYC to promote tumorigenesis of HSC. 
 
3.3.2 Expression of BCL-XL but not of the inhibitor of the receptor-mediated anti-
apoptotic pathway FLIPL drives MYC-driven tumorigenesis towards acute myeloid 
leukemia (Paper III).  
Acute myeloid leukemia is characterized by a clonal expansion of HSCs and myeloid 
progenitors cells that have undergone malignant transformation. MYC is often overexpressed 
in AML due to mutations and translocations events.  Aiming to determine the spectrum of 
tumors produced in mice transduced with Mock/MYC, MYC/BCL-XL and MYC/FLIPL, cell 
suspensions from hematopoietic tissues were analyzed by flow cytometry using myeloid, T-
cell, B-cell and erythroid markers.  Mice reconstituted with HSCs expressing Mock/MYC 
developed myeloid leukemia and T-cell lymphoma, in agreement with previous reports [122]. 
The two tumor types localized to different hematopoietic compartments; the bone marrow 
displayed tumors of myeloid origin and the thymus and  enlarged lymph nodes  displayed  T-
cell tumors.  Spleen and the infiltrated liver often showed a mixed population of both myeloid 
and lymphoid origin.  In contrast, the vast majority of cells dominating the hematopoietic 
compartments of MYC/BC-LXL mice were myeloid (CD11b
+
, Gr1
+
) AML-like cells. In 
addition, the MYC/BCL-XL mice had a pronounced increase in the total number of white 
blood cells compare to Mock/Mock transplanted mice.  Differential count analysis confirmed 
that approximately 50% of cells in MYC/BCL-XL transplanted mice were blasts. These 
results suggest that the anti-apoptotic protein BCL-XL drives MYC-driven tumorigenesis 
towards acute myeloid leukemia. Our results differ from a study performed by Luo et al. 
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[123]. Their results indicated that expression of MYC alone in bone marrow cells that were 
transplanted into recipient mice solely gave rise to acute myeloid leukemia. They also argued 
that co-expression of MYC and BCL-2 gave rise to a mixture of AML and pre-B acute 
lymphoid leukemia in BALB/c mice. One explanation to this discrepancy in the two studies 
results could be that tumor initiating MYC target cells differs between the systems. Another 
possibility is that Luo et al used unfractionated mononuclear bone marrow cells, whereas we 
transduced Lin- bone marrow cells.  Besides the paper by Luo et al., another study reported 
that overexpression of MYC results in development of aggressive pre-B lymphomas with low 
penetrance [124]. One possible explanation why their results differ from ours relies on the 
fact that they used retrovirally transduced fetal liver cells (E14.5), and therefor may hit 
another tumor-initiating cell.  
 
We next generalized our results to other apoptotic member of the BCL-2 family and to other 
strains of mice.  Isolated HSCs were transduced with MYC together with BCL-XL or BCL-2. 
These HSCs were then transplanted in to BALB/c recipient mice. The transplanted mice 
rapidly developed similar AML-like disease as the DBA/2 mice transplanted with HSCs over 
expressing BCL-XL and MYC.  The MYC/BCL-XL BALB/c mice had a mean survival of 16 
days while the MYC/BCL-2 BALB/c mice had a mean survival of 19 days. The noticed 
minor difference in survival between these mice was statistically significant and might be 
explained by the lower proportion of BCL-2/MYC double expressing cells among the 
transplanted cells. Both group of animals also showed grossly enlarged spleens with means 
values of 757 mg for BCL-XL/MYC BALB/c and 899 mg for BCL-2/MYC BALB/c. As in 
the analysis of the DBA/2 mice, the tumors found in the BCL-XL/MYC predominantly 
expressed myeloid markers (CD11b and Gr1). In contrast, the FLIPL/MYC BALB/c mice 
developed myeloid tumors (Gr1
+
 CD11b
+
 and/or Gr1
+
) or CD4
+
 T-cell lymphoma.  Infiltrated 
liver and spleen of these animals often showed a mixed population of both myeloid and 
lymphoid origin similar to Mock/MYC mice.  Interestingly, the CD4
+
CD8+ lymphoid tumor 
cells population was diminished among FLIPL/MYC-induced T-cell lymphoma cells 
compared to the lymphoma cells expressing only MYC. This was accompanied by an 
increased CD4
+
 population of cells, thus suggesting that FLIPL is involved in the selection of 
MYC-induced lymphoid but not of myeloid tumors.  We also confirmed the flow cytometric 
results by immunohistochemical analysis. Spleen and liver tissue sections were stained with 
antibodies against T-cell markers (CD45R, CD3) and myeloid marker (myeloid peroxidase, 
MPO).  Mock/MYC spleen and liver tissues were extensively positive for CD3 and MPO 
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markers. CD3
+
 cells were mostly distributed as perivascular cuffs in liver tissues whereas the 
myeloid (MPO
+
) cells showed a more diffuse distribution. Moreover, the spleen architecture 
was grossly distorted and the tissue was predominately positive for CD3 and MPO markers.  
Mock/Mock spleen tissue showed normal organ architecture and the liver did not show any 
sign of tumor infiltration. MYC/BCL-XL and MYC/BCL2 spleen and liver tissues only 
expressed the myeloid marker MPO.  Immunohistochemical analysis of tumor cells presented 
in all analyzed tissues showed similar staining patters as Mock/MYC.  These results suggest 
that Mock/MYC mice mainly developed myeloid leukemia and lymphoblastic T-cell 
lymphoma.  Coexpression of the anti apoptotic family members (BCL-XL and BCL-2) and 
MYC strongly favored tumor development towards myeloid leukemia. Further, coexpression 
of MYC and FLIPL did not affect the distribution of myeloid versus lymphoid tumors cells, 
but changed the ratio between single CD4+ and double positive CD4
+
CD8
+
 T cell 
lymphomas.  
 
3.3.3 Expansion of myeloid leukemic cells in MYC and MYC/BCL-XL expressing mice 
at the expense of other hematopoietic cell populations  (Paper III) 
We next investigated the kinetics behind lymphoma/leukemia development and the effect of 
MYC and MYC/BCL-XL expression on the different blood cell populations. Hematopoietic 
development was studied at different time points (7, 14 and 35 days) after transplantation of 
Mock/MYC or MYC/BCL-XL transduced cells in recipient mice. The percentage of cells 
expressing MYC-YFP was almost constant (about 50% of all cells) at day 7 and 35 after 
transplantation, but this population underwent a rapid expansion after 35 days. In the other 
hand Mock-GFP/Mock-YFP-expressing cells did not expand but stayed at a constant level. In 
contrast, BCL-XL-GFP/MYC-YFP-expressing cells rapidly expanded from day 7 to day 14 
after transplantation. BCL-XL-GFP/MYC-YFP expressing cells in the bone marrow expanded 
from 20% at day 7 to 75% at day 14 and in the spleen these cells expanded from about 20% at 
day 7 to 40% at day 14. The phenotype of the cells expressing Mock-GFP, MYC-YFP and 
BCL-XL-GFP/MYC-YFP were also analyzed at different time points.  MYC expressing 
myeloid cells accounted for around 60% of the cells in the bone marrow and 20-30% of the 
cell in the spleen at day 7. MYC expression was also detected in pre-B, B, CD4
+
 and CD8
+
 T 
cells and in erythroid cells.  However, these populations did no undergo expansion days 7-14, 
but there was a tendency towards a B-cell or T-cell expansion at day 35.  BCL-XL-
GFP/MYC-YFP expressing pre-B, B, CD4
+
 and CD8
+
 T cells as well as erythroid 
Ter119+CD71
hi
 and Ter119+CD71
low
 cells could be found at day 14. However the vast 
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majority of cells expressing BCL-XL-GFP/MYC-YFP were found among myeloid CD11b
+
 
Gr1
+
 cells.  In summary the above results suggest that the myeloid CD11
+
 Gr1
+
 population 
dominated at early time pints both of mice transplanted with MTC-YFP and BCL-XL-
GFP/MYC-YFP expressing HSCs.  
 
3.3.4 Blast transformation of myeloid and lymphoid cells in MYC and MYC/BCL-XL 
(Paper III).  
Activation and blast transformation were investigated by the analysis of the mean 
fluorescence intensity in forward scatter (∆mfi) in CD11b+Gr1+, CD19+IgM- and CD19+IgM 
cells from bone marrow and spleen from 7, 14 and 35 days after transplantation.  MYC-
YFP/BCL-XL-GFP AND MYC expressing cells were shown to be blast transformed 
compared to non-transduced cells, Mock-GFP cells or cells expressing only BCL-XL-GFP in 
the same animal.   MYC/BCL-XL cells expressing CD19
+
Ig
+
B cells markers showed an 
increased cells size compared to cells expressing MYC alone. The noticed cell size might 
suggest that these cells also had an increase cell survival due to the expression of BCL-XL. In 
any case it was mainly MYC and MYC/BCL-XL expressing myeloid CD11+Gr-1+ cells that 
expanded rapidly and reached elevated steady-state levels.  Our results suggest that mice 
transplanted with HSC overexpressing MYC or MYC/BCL-XL contained high numbers of 
pre-malignant MYC-expressing cells of different lineages.  The populations remained at 
constant steady-state levels until 6-7 weeks after transplantation in MYC expressing mice.  
 
Recently, different reports have implicated MYC in the regulation of oncogene-induced 
senescence. For instance, Campaner et al reported that loss of CDK2 together with ectopic 
MYC expression sensitized MEFS to senescence, increase senescence in pancreatic B-cell 
tumors and delayed the onset of MYC-driven lymphoma. Moreover, Hydbring et al 
demonstrated that suppression of RAS-induced senescence by MYC in REFs is associated 
with CDK2 activity. The authors demonstrated that phosphorylation of MYC at Ser 62 by 
CDK2 plays a crucial role in MYC repression of cellular senescence. We first aimed to clarify 
and to corroborate if specific CDK2 inhibition promotes MYC induction of senesce in HSCs 
transduced with MYC and BCL-XL. The transduced HSCs were treated for five days with the 
CDK2 inhibitor CVT2584 and scored for senescence. The selective inhibition of CDK2 
reduced the proliferation of the transduced HSCs. In addition CDK2 inhibition induced 
cellular senescence in the MYC/BCL-XL transduced cells (paper IV). 
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3.4 Pharmacological inhibition of CDK2 improves the survival of MYC/BCL-XL mice 
(Paper IV) 
The in vitro results showed that pharmacological inhibition of CDK2 lead to the induction of 
senescence in MYC/BCL-XL transduced HSCs. Based on these results we next aimed to 
inhibit CDK2 in an in vivo mouse model. For this purpose we used a bone marrow 
transplantation mouse model described in paper III [122]. In this setting isolated bone marrow 
HSCs were retrovirally transduced with MYC and BCL-XL and transplanted into lethally 
irradiated mice.  As described above the mice started to show sings of the disease 2 weeks 
after transplantation and rapidly become terminally ill due to the development of acute 
myeloid leukemia. Three to six days after HSC reconstitution the mice were treated with 
different concentrations of the CDK2 inhibitor CVT2584 and DMSO respectively. Two 
modalities of administration were used; either via IP injections on a daily basis or continuous 
supply via  osmotic minipumps. Control mice became moribund 2-3 weeks after 
transplantation as expected and pharmacological inhibition of CDK2 improved mice survival 
with 3-4 days regardless modality of treatment. The mice were also treated with the 
topoisomerase inhibitor adriamycin (ADR) as a reference. Treatment with this well-known 
anticancer drug also gave same survival as the CDK2 inhibitor. However, benefits with 
CVT2584 are that it is more selective than ADR and, in contrast to ADR, does not seem to 
cause DNA damage (data not shown).  Furthermore, one advantage in this type of treatment 
approach is that CDK2 is a non-essential gene; pharmacological inhibition of CDK2 is likely 
to give less side effects in a clinical setting. 
  
3.4.1 CDK2 inhibition delays the onset of MYC driven leukemia by the induction of 
cellular senescence  (Paper IV) 
We next explored the nature of the delayed onset of MYC driven leukemia observed in the 
CVT2584 treated mice. Our studies showed that this was primarily due to the induction of 
cellular senescence as demonstrated by increased SA-beta-gal activity and H3K9me
3
 
heterochromatin foci formation, the strongly reduced proliferation rates and cellularity in 
analyzed spleen, liver and bone marrow tissues and lack of apoptosis in CVT2584 treated 
MYC/BCL-XL mice. Interestingly, we also detected the presence of F4/80 activated 
macrophages in spleen tissues of CT2584 treated animals. Taken together these results 
suggest that the pharmacological inhibition of CDK2 forced parts of the leukemic population 
into senescence and activated circulating/resident macrophages that may take part in the 
clearance of senescent AML cells.  
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3.4.2 Pharmacological inhibition of CDK2 in MYC/BCL-XL mice reduces MYC 
phosphorylation and induces the senescence program by engaging the p53/p19Arf/p21  
and pRb pathways (Paper IV) 
Previous results have shown that MYC phosphorylation by CDK2 seems to play an important 
role in the MYC-mediated suppression of oncogene induced senescence [117]. Our results 
show that MYC phosphorylation was significantly reduced in all mice administered with the 
CDK2 inhibitor CVT2584. Protein analysis also revealed that pharmacological inhibition of 
CDK2 in the MYC/BCL-XL mice led to the up-regulation of p19ARF  and the CDKI p21, as 
well as activation of pRb, which all are important effectors of senescence. The observed up-
regulation of these proteins and activation of pRb indicate that the selective inhibition of 
CDK2 in the MYC/BCL-XL leukemic mice induced the senescence program trough the 
activation of p53/p19Arf/p21 and pRb pathways. These results are in agreement with previous 
results published by Campaner et al, where a similar senescence program is induced in 
cultured MEFS lacking CDK2. 
  
In summary our results suggest that the pharmacological inhibition of CDK2 improved mice 
survival with 3-4 days and delayed the onset of MYC driven leukemia by the induction of 
cellular senescence. However, the CDK2 inhibition in this model only gave moderate mice 
survival. One should bear in mind that this is a very aggressive tumor model with massive and 
extremely rapid expansion of MYC/BCL-XL leukemic cells leading to death in 2-3 weeks. 
The effectiveness of the treatment might be masked by tumor aggressiveness in this mouse 
model. Therefore other less aggressive models could be used in other to further evaluate the 
efficacy of CDK2 inhibition for treatment of MYC driven tumorigenesis. Nevertheless, our 
result showed that CDK2 inhibition led to a significant improvement of survival in a very 
aggressive tumor model, and the concept of CDK2 inhibition as a potential new pro-
senescence treatment strategy against tumors driven by MYC should be evaluated further. 
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4. Conclusions  
 
¥ Stable gradients of VEGFA165 efficiently induced chemotaxis but not chemokinesis  
of endothelial cells 
 
¥ A gradient of VEGFA121 was shown to guide endothelial cells, suggesting that 
VEGFA does not need to interact directly with proteoglycan and neuropilin co-
receptors to induce chemotaxis 
 
¥ Gradients of FGF2 weakly attract venular cells but not arterial cells 
 
¥ Lymph vessel formation in the embryonic mouse kidney predominantly occurs via 
invasive sprouting from the surrounding tissue  
 
¥ Cells present within the developing kidney were shown to occasionally express 
lymphatic markers 
 
 
¥ The anti-apoptotic proteins of the intrinsic pathway accelerate the development of  
MYC-driven hematopoietic tumors to a larger extent of those that the extrinsic 
pathway of apoptosis  
 
¥ Pharmacological inhibition of CDK2 improved mice survival with 3-4 days and 
delayed the onset of MYC driven leukemia by the induction of cellular senescence.  
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